Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.

about

How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.

P2860

Q52668325-93B8675A-AF71-4835-B259-629DDBD106A6

P2860

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.

Item

http://www.wikidata.org/entity/Q36252792

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical and Immune Effects of ...... th Advanced Pancreatic Cancer.

@ast

Clinical and Immune Effects of ...... th Advanced Pancreatic Cancer.

@en

type

Item

label

Clinical and Immune Effects of ...... th Advanced Pancreatic Cancer.

@ast

Clinical and Immune Effects of ...... th Advanced Pancreatic Cancer.

@en

prefLabel

Clinical and Immune Effects of ...... th Advanced Pancreatic Cancer.

@ast

Clinical and Immune Effects of ...... th Advanced Pancreatic Cancer.

@en

P1476

Clinical and Immune Effects of ...... th Advanced Pancreatic Cancer.

@en

P2093

Fariba Mozaffari

http://www.w3.org/2001/XMLSchema#string

Gustav J Ullenhag

http://www.w3.org/2001/XMLSchema#string

Håkan Mellstedt

http://www.w3.org/2001/XMLSchema#string

Maria Liljefors

http://www.w3.org/2001/XMLSchema#string

Mats Broberg

http://www.w3.org/2001/XMLSchema#string

P2860

Intrinsic disorder in cell-signaling and cancer-associated proteins

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Lenalidomide therapy for metastatic renal cell carcinoma.

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.

Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.

A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.

P304

e0169736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0169736

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28099502

http://www.w3.org/2001/XMLSchema#string

P932

5242484

http://www.w3.org/2001/XMLSchema#string

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.

about

P2860

P2860

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932